Niagen Bioscience (NASDAQ:NAGE – Get Free Report) and Edgewell Personal Care (NYSE:EPC – Get Free Report) are both small-cap consumer staples companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.
Valuation & Earnings
This table compares Niagen Bioscience and Edgewell Personal Care”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Niagen Bioscience | $122.29 million | 1.34 | $17.38 million | $0.12 | 17.25 |
| Edgewell Personal Care | $2.00 billion | 0.63 | $25.40 million | ($1.11) | -24.60 |
Edgewell Personal Care has higher revenue and earnings than Niagen Bioscience. Edgewell Personal Care is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Niagen Bioscience and Edgewell Personal Care’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Niagen Bioscience | 8.37% | 10.18% | 7.57% |
| Edgewell Personal Care | -2.59% | 6.17% | 2.52% |
Analyst Ratings
This is a breakdown of recent ratings and price targets for Niagen Bioscience and Edgewell Personal Care, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Niagen Bioscience | 0 | 1 | 4 | 1 | 3.00 |
| Edgewell Personal Care | 1 | 5 | 3 | 0 | 2.22 |
Niagen Bioscience presently has a consensus target price of $8.50, indicating a potential upside of 310.63%. Edgewell Personal Care has a consensus target price of $31.83, indicating a potential upside of 16.58%. Given Niagen Bioscience’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Niagen Bioscience is more favorable than Edgewell Personal Care.
Institutional and Insider Ownership
15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 91.9% of Edgewell Personal Care shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Comparatively, 3.0% of Edgewell Personal Care shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Niagen Bioscience has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500. Comparatively, Edgewell Personal Care has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500.
Summary
Niagen Bioscience beats Edgewell Personal Care on 12 of the 15 factors compared between the two stocks.
About Niagen Bioscience
Niagen Bioscience, Inc. develops and markets products based on nicotinamide riboside (NR), a form of vitamin B3 studied for its role in supporting the body’s production of NAD+. Its offerings include Tru Niagen, a consumer dietary supplement, and Niagen, a branded NR ingredient supplied to other businesses. The company also conducts and supports research on NR, NAD+ and healthy aging. It was formerly known as ChromaDex Corporation and adopted the Niagen Bioscience name in 2025. Niagen Bioscience serves consumers and commercial customers in the United States and international markets through online sales, retail and distribution channels.
About Edgewell Personal Care
Edgewell Personal Care is a global consumer products company focused on personal grooming and sun and skin care. Its products include shaving systems, disposable razors, shaving gels and creams, sunscreens and skin care products, sold through retailers and online channels. Its brand portfolio includes Schick, Wilkinson Sword, Edge, Skintimate, Billie, Banana Boat, Hawaiian Tropic, Bulldog and Jack Black. The company serves consumers in the United States and international markets. Edgewell became an independent public company in 2015 following its separation from Energizer Holdings.
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
